It is expected that the stepwise field cancerization process varies in the NAT of each patient because the tumor of each patient develops as a result of different initial mutations and various subsequent evolutionary paths that are influenced by patient-specific natural selection. This evidence concerns the gene BRD2 and neoplasm.